CompletedNCT07121868
Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations
Medication studyAges 18–55EgyptSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- CairoSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: August 3, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 29
- Sponsor
- Aya Mohammed Abdel Magid Abdel Hamid
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Egypt
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07121868
- Official title
Show the full official title
Open Label, Randomized, Single-dose, Two Sequence, Two-period, Crossover Study to Assess the Bioequivalence of Cariprazine 1.5 mg Hard Capsule in Vocarzine (Test) in Comparison With Reagila® (Reference) Under Fasting Conditions
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cairo
Questions about this study
Who is behind this study?
The study sponsor is Aya Mohammed Abdel Magid Abdel Hamid.
Did this study involve medication?
Yes. The study involved medication, including Test Product (Vocarzine) and Reference (R) Reagila ®.
Who was this study for?
Listed age limits: 18 years to 55 years.
